📰 BloombergBloombergDoubao · 实盘不做把握 7/10不做原因:风险收益比不佳
北京时间·🕒 发布 03:38:02·⟳ 抓取 03:43:43 +5m41s·⚡ 决策 10-22 03:46:25 +2m42s·5.8 天前
EQT 接近以约96亿欧元（46.50欧元/股）收购分子诊断公司 Qiagen，董事会或很快批准
并购套利盈亏比不对称：QGEN.US 现价49.74美元，46.50欧元要约（约50.6美元）仅剩约1.5-2%上行；协议尚未签署（最终决定未作出、三方拒评），且有2020年赛默飞收购谈崩先例，破裂后大概率回落至传闻前44-46美元（约-8%~-11%）。同时 KKR 仍可能加价、PSquared 要求高于50美元，做空亦无安全边际，多空均不做。
📄 原文Bloomberg↗ 原文
EQT AB is nearing a deal to acquire Qiagen NV for around €9.6 billion ($10.8 billion) bringing an end to years of takeo…
不做 Qiagen NV（QGEN.US）
并购套利盈亏比不对称：现价49.74美元距46.50欧元要约（约50.6美元）仅约1.5-2%，而协议未签署、三方拒评、股东 PSquared 要求高于50美元、有2020年谈崩先例，破裂后大概率回落至44-46美元（-8%~-11%）；向上亦有 KKR 加价可能使做空无安全边际。多空均无正期望，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
EQT 收购 Qiagen 进入临门一脚属实质进展，但市场已连续两日重定价（10月20日+5%、今日盘中再涨1.7%至49.7美元），股价基本贴近46.50欧元要约价，套利空间不足2%而破裂回撤风险8%以上，盈亏比不支持入场。
🔎 新鲜度:最早出现 2026-10-20 · 扩散 medium · price-in 风险 high ↗
关键理由
- 要约价46.50欧元（约50.6美元）较 QGEN.US 现价49.74美元仅约1.5-2%空间，年化前的确定性收益极薄
- 交易尚未经董事会最终批准且各方拒评，叠加2020年赛默飞要约失败先例，破裂下行（-8%~-11%）远大于成交上行
主要风险
- 若 KKR 最后加价或 EQT 提价至50美元以上，股价可能再跳涨1-3%，但此为不可预测的竞价结果而非可承担的套利edge
- 协议达成后至交割仍有监管与要约接受率风险，2020年即因激进投资者反对导致要约不足而失败
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-21 · 影响 weakens
大股东 PSquared 公开希望以高于50美元/股成交，可能抵制46.50欧元报价；2020年要约曾因股东反对失败；协议尚未签署。
检索:Qiagen QGEN deal fail shareholder opposition PSquared KKR bid 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-10-21 · 影响 invalidates
KKR 此前已出价，存在最后加价或竞价升级可能，且协议最快今日宣布，做空面临逼空式跳涨风险。
检索:KKR topping bid Qiagen EQT deal announcement 原文 ↗
先例如何影响了这次决策
对本次决策的影响:强化 AVOID：在仅剩约2%套利空间时，破裂先例使下行风险显著占优。
方向:本轮未调用历史先例面板；文中所载2020年赛默飞收购 Qiagen 失败为本主体最直接的破裂先例，提示签约前与要约阶段均有真实失败概率。
涨幅量级:无足够对齐先例校准幅度；以前一交易日传闻涨幅（+5%）与当前价差直接判断套利空间。
形态:本主体有收购传闻→要约失败→股价回落的见光死式先例，而非稳定成交先例。
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,797 ms
{"result": "search_processed_events:agent query=`eqt acquire qiagen €46.50 bid | eqt qiagen buyout deal near | qiagen takeover eqt 9.6 billion molecular testing`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、26606 条本臂决策(完整)，返回 1 条候选。\n• 10-20 17:46 UTC(北京 10-21 01:46) [bm25:57%] 不做 KKR.US,QGEN.US (bloomberg) - stock_quote 成功 stock_tools HTTP · 199 ms
{
原文全文
展开原文 · 1,799 字
EQT AB is nearing a deal to acquire Qiagen NV for around €9.6 billion ($10.8 billion) bringing an end to years of takeover speculation involving the European molecular testing company, according to people familiar with the matter.
Qiagen’s board is close to approving the buyout firm’s bid of €46.50 a share and could announce a deal as soon as Wednesday, said the people, who asked not to be identified because the information was private. A final decision hasn’t been made, the people said.
Representatives for EQT and Qiagen declined to comment.
Shares in Qiagen closed at €42.82 a share Wednesday in Frankfurt for a market value of €8.55 billion.
The deal would rank as one of the largest in the European healthcare sector this year. KKR & Co. had also bid for the company.
Qiagen has already been urged to accept the proposal. Bloomberg reported this week that Switzerland-based PSquared Asset Management, a top 25 holder of Qiagen, wants to see a deal done at more than $50 a share.
The company provides technologies and services for testing genetic materials to hundreds of thousands of customers, including pharmaceutical research and development teams and clinical labs. It has attracted takeover interest multiple times in recent years. Thermo Fisher Scientific Inc. made a $12 billion takeover bid for Qiagen in 2020, before eventually abandoning it when opposition from an activist investor led its tender offer to fall short.
EQT is in the midst of a prolific run of dealmaking that has resulted in number of multibillion-dollar transactions this year. The Stockholm-based firm this week agreed a A$9.3 billion acquisition of Australia’s Cleanaway Waste Management Ltd. Over the summer, EQT struck a £9.3 billion takeover of UK-listed product testing business Intertek Group Plc.
Qiagen’s board is close to approving the buyout firm’s bid of €46.50 a share and could announce a deal as soon as Wednesday, said the people, who asked not to be identified because the information was private. A final decision hasn’t been made, the people said.
Representatives for EQT and Qiagen declined to comment.
Shares in Qiagen closed at €42.82 a share Wednesday in Frankfurt for a market value of €8.55 billion.
The deal would rank as one of the largest in the European healthcare sector this year. KKR & Co. had also bid for the company.
Qiagen has already been urged to accept the proposal. Bloomberg reported this week that Switzerland-based PSquared Asset Management, a top 25 holder of Qiagen, wants to see a deal done at more than $50 a share.
The company provides technologies and services for testing genetic materials to hundreds of thousands of customers, including pharmaceutical research and development teams and clinical labs. It has attracted takeover interest multiple times in recent years. Thermo Fisher Scientific Inc. made a $12 billion takeover bid for Qiagen in 2020, before eventually abandoning it when opposition from an activist investor led its tender offer to fall short.
EQT is in the midst of a prolific run of dealmaking that has resulted in number of multibillion-dollar transactions this year. The Stockholm-based firm this week agreed a A$9.3 billion acquisition of Australia’s Cleanaway Waste Management Ltd. Over the summer, EQT struck a £9.3 billion takeover of UK-listed product testing business Intertek Group Plc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
95435cbf23· 2026-10-22 03:46 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前